Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuzatrelvir Relative Bioavailability and Food Effect Study in Healthy Adults
NCT07552779Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve from time zero to infinity at 48 hours and Maximum Plasma Concentration at 48 hours. Started Apr 2026; status: completed.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07552779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552779.